Lipocine Inc. (NASDAQ:LPCN)’s share price was up 1.9% during trading on Friday . The stock traded as high as $3.90 and last traded at $3.77, with a volume of 53,483 shares traded. The stock had previously closed at $3.70.

Separately, Canaccord Genuity reaffirmed a “buy” rating and set a $6.00 price target (down previously from $15.00) on shares of Lipocine in a research report on Saturday, July 2nd.

The stock has a 50-day moving average price of $3.62 and a 200 day moving average price of $7.97. The firm’s market cap is $67.01 million.

Lipocine (NASDAQ:LPCN) last released its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.05. Equities analysts expect that Lipocine Inc. will post ($1.31) EPS for the current fiscal year.

An institutional investor recently raised its position in Lipocine stock. Dimensional Fund Advisors LP raised its position in shares of Lipocine Inc. (NASDAQ:LPCN) by 73.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 271,272 shares of the specialty pharmaceutical company’s stock after buying an additional 114,448 shares during the period. Dimensional Fund Advisors LP owned 1.49% of Lipocine worth $3,508,000 at the end of the most recent quarter.

Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.